Binding affinity, specificity and comparative biodistribution of the parental murine monoclonal antibody MX35 (Anti-NaPi2b) and its humanized version Rebmab200

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Lindegren, Sture ^a   Andrade, Luciana N S ^b,c   Bäck, Tom ^a   Machado, Camila Maria L ^c   Horta, Bruno Brasil ^b   Buchpiguel, Carlos ^c   Moro, Ana Maria ^d   Okamoto, Oswaldo Keith ^b,c   Jacobson, Lars ^a   Cederkrantz, Elin ^a   Washiyama, Kohshin ^a   Aneheim, Emma ^a   Palm, Stig ^a   Jensen, Holger ^e   Tuma, Maria Carolina B ^b   Chammas, Roger ^c   Hultborn, Ragnar ^a   Albertsson, Per ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Recepta Biopharma   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d INSTITUTO BUTANTAN   (Brazil)

^e University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASTATINE 211; DIAGNOSTIC AGENT; EPITOPE; HYDAZINO NICOTINAMIDE TC 99M; IODINE 125; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MX35; MONOCLONAL ANTIBODY REBMAB200; TECHNETIUM 99M; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ASTATINE; RADIOPHARMACEUTICAL AGENT; SLC34A2 PROTEIN, HUMAN; SODIUM PHOSPHATE COTRANSPORTER 2B; TECHNETIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; DRUG SPECIFICITY; HUMAN; HUMAN CELL; IMAGING; IMMOBILIZATION; IN VITRO STUDY; IN VIVO STUDY; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; OVARY CARCINOMA; RADIODIAGNOSIS; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CARCINOMA; CHEMISTRY; DIAGNOSTIC IMAGING; DRUG SCREENING; FEMALE; GENE EXPRESSION; GENETICS; IMMUNOLOGY; METABOLISM; OVARIAN NEOPLASMS; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

MURINAE; MUS; MUS MUSCULUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; ASTATINE; CARCINOMA; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; SODIUM-PHOSPHATE COTRANSPORTER PROTEINS, TYPE IIB; TECHNETIUM; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929379768     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126298     Document Type: Article

References (30)

1. Hamilton JG, Asling CW, Garrison WG, Jue B, Scott KG, Wallace PC, et al. The destruction of thyroid tissue in the rat by the halogen, astatine. J Clin Invest. 1950; 29(6):820. Epub 1950/06/01. PubMed PMID: 15436748.
2. Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr Pharm Des. 2000; 6(14):1433-55. Epub 2000/07/21. PubMed PMID: 10903402.
3. Andersson H, Lindegren S, Back T, Jacobsson L, Leser G, Horvath G. The curative and palliative potential of the monoclonal antibody MOv18 labelled with 211At in nude mice with intraperitoneally growing ovarian cancer xenografts - a long-term study. Acta Oncol. 2000; 39(6):741-5. Epub 2000/12/29. PubMed PMID: 11130014.
4. Elgqvist J, Andersson H, Bernhardt P, Back T, Claesson I, Hultborn R, et al. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2. Int J Radiat Oncol Biol Phys. 2006; 66(4):1228-37. Epub 2006/12/06. doi: 10.1016/j. ijrobp.2006.07.003 PubMed PMID: 17145538.
5. Elgqvist J, Bernhardt P, Hultborn R, Jensen H, Karlsson B, Lindegren S, et al. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice. J Nucl Med. 2005; 46(3):464-71. Epub 2005/03/08. PubMed PMID: 15750160.
6. Andersson H, Cederkrantz E, Back T, Divgi C, Elgqvist J, Himmelman J, et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2 - a phase I study. J Nucl Med. 2009; 50(7):1153-60. Epub 2009/06/16. doi: 10.2967/jnumed.109.062604 PubMed PMID: 19525452.
7. Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, et al. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 2008; 49(1):30-8. Epub 2007/12/14. doi: 10.2967/jnumed.107.046938 PubMed PMID: 18077533; PubMed Central PMCID: PMC2832604.
8. Zalutsky MR. Current status of therapy of solid tumors: brain tumor therapy. J Nucl Med. 2005; 46 Suppl 1:151S-6S. PubMed PMID: 15653663.
9. Mattes MJ, Look K, Furukawa K, Pierce VK, Old LJ, Lewis JL Jr., et al. Mouse monoclonal antibodies to human epithelial differentiation antigens expressed on the surface of ovarian carcinoma ascites cells. Cancer research. 1987; 47(24 Pt 1):6741-50. PubMed PMID: 3677104.
10. Yin BW, Kiyamova R, Chua R, Caballero OL, Gout I, Gryshkova V, et al. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas. Cancer immunity. 2008; 8:3. PubMed PMID: 18251464; PubMed Central PMCID: PMC2935786.
11. Mirick GR, Bradt BM, Denardo SJ, Denardo GL. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. The quarterly journal of nuclear medicine and molecular imaging: official publication of the Italian Association of Nuclear Medicine. 2004; 48(4):251-7. PubMed PMID: 15640788.
12. Lopes dos Santos M, Yeda FP, Tsuruta LR, Horta BB, Pimenta AA Jr., Degaki TL, et al. Rebmab200, a humanized monoclonal antibody targeting the sodium phosphate transporter NaPi2b displays strong immune mediated cytotoxicity against cancer: a novel reagent for targeted antibody therapy of cancer. PloS one. 2013; 8(7):e70332. doi: 10.1371/journal.pone.0070332 PubMed PMID: 23936189; PubMed Central PMCID: PMC3729455.
13. Gainkam LO, Huang L, Caveliers V, Keyaerts M, Hernot S, Vaneycken I, et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med. 2008; 49(5):788-95. doi: 10.2967/jnumed.107.048538 PubMed PMID: 18413403.
14. Vaneycken I, Govaert J, Vincke C, Caveliers V, Lahoutte T, De Baetselier P, et al. In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. J Nucl Med. 2010; 51(7):1099-106. doi: 10.2967/jnumed.109.069823 PubMed PMID: 20554727.
15. Flook AM, Yang J, Miao Y. Evaluation of new Tc-99m-labeled Arg-X-Asp-conjugated alpha-melanocyte stimulating hormone peptides for melanoma imaging. Molecular pharmaceutics. 2013; 10(9):3417-24. doi: 10.1021/mp400248f PubMed PMID: 23885640; PubMed Central PMCID: PMC3866226.
16. Malviya G, Anzola KL, Podesta E, Lagana B, Del Mastro C, Dierckx RA, et al. (99m)Tc-labeled rituximab for imaging B lymphocyte infiltration in inflammatory autoimmune disease patients. Molecular imaging and biology: MIB: the official publication of the Academy of Molecular Imaging. 2012; 14(5):637-46. doi: 10.1007/s11307-011-0527-x PubMed PMID: 22127469; PubMed Central PMCID: PMC3443359.
17. Lindegren S, Back T, Jensen HJ. Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. Appl Radiat Isot. 2001; 55(2):157-60. Epub 2001/06/08. PubMed PMID: 11393754.
18. Lindegren S, Frost S, Back T, Haglund E, Elgqvist J, Jensen H. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate. J Nucl Med. 2008; 49(9):1537-45. Epub 2008/08/16. doi: 10.2967/jnumed.107.049833 PubMed PMID: 18703591.
19. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984; 72(1):77-89. Epub 1984/08/03. PubMed PMID: 6086763.
20. Elgqvist J, Andersson H, Back T, Hultborn R, Jensen H, Karlsson B, et al. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35. J Nucl Med. 2005; 46(11):1907-15. PubMed PMID: 16269606.
21. Elgqvist J, Andersson H, Jensen H, Kahu H, Lindegren S, Warnhammar E, et al. Repeated Intraperitoneal alpha-Radioimmunotherapy of Ovarian Cancer in Mice. Journal of oncology. 2010; 2010:394913. doi: 10.1155/2010/394913 PubMed PMID: 19859581; PubMed Central PMCID: PMC2766502.
22. Andersson H, Lindegren S, Back T, Jacobsson L, Leser G, Horvath G. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18. Anticancer Res. 2000; 20(1A):459-62. Epub 2000/04/19. PubMed PMID: 10769696.
23. Leinster DA, Kulbe H, Everitt G, Thompson R, Perretti M, Gavins FN, et al. The peritoneal tumour microenvironment of high-grade serous ovarian cancer. The Journal of pathology. 2012; 227(2):136-45. doi: 10.1002/path.4002 PubMed PMID: 22322968; PubMed Central PMCID: PMC3609073.
24. Kuus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M, Kay NE. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clinical and diagnostic laboratory immunology. 1994; 1(4):365-72. PubMed PMID: 8556470; PubMed Central PMCID: PMC368269.
25. Maher VE, Drukman SJ, Kinders RJ, Hunter RE, Jennings J, Brigham C, et al. Human antibody response to the intravenous and intraperitoneal administration of the F(ab')2 fragment of the OC125 murine monoclonal antibody. Journal of immunotherapy: official journal of the Society for Biological Therapy. 1992; 11(1):56-66. PubMed PMID: 1734949.
26. Visser GWM, Diemer EL, Kaspersen FM. The Nature of the Astatine-Protein Bond. Int J Appl Radiat Is. 1981; 32(12):905-12. doi: 10.1016/0020-708x(81)90077-6 PubMed PMID: WOS:A1981MU65800009.
27. Zalutsky MR, Narula AS. A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine. International journal of radiation applications and instrumentation Part A, Applied radiation and isotopes. 1987; 38(12):1051-5. PubMed PMID: 2828275.
28. Goldenberg DM, Chang CH, Rossi EA, McBride WJ, Sharkey RM. Pretargeted Molecular Imaging and Radioimmunotherapy. Theranostics. 2012; 2(5):523-40. doi: 10.7150/Thno.3582 PubMed WOS:000304488100010. PMID: 22737190
29. Knight JC, Cornelissen B. Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy. American journal of nuclear medicine and molecular imaging. 2014; 4(2):96-113. PubMed PMID: 24753979; PubMed Central PMCID: PMC3992206.
30. Wu AM. Engineered antibodies for molecular imaging of cancer. Methods. 2014; 65(1):139-47. doi: 10.1016/j.ymeth.2013.09.015 PubMed PMID: 24091005; PubMed Central PMCID: PMC3947235.